BioVersys AG
Swiss clinical-stage biopharmaceutical company developing novel antibacterial therapies to combat antimicrobial resistance (AMR) and tuberculosis.
Last updated September 28, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
BioVersys AG is a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial therapies to combat antimicrobial resistance (AMR) and tuberculosis. The company describes AMR as a "silent pandemic" that threatens global healthcare systems, citing 1.27 million casualties directly linked to drug-resistant infections and projecting 10 million annual deaths by 2050 if no action is taken. BioVersys positions itself as a resistance fighter, using innovation to save lives and improve patient outcomes. The company's pipeline includes BV100, a novel mechanism-of-action drug candidate targeting serious hospital infections caused by Acinetobacter baumannii; Alpibectir, a novel potentiator with a new mechanism of action for multidrug-resistant tuberculosis (MDR-TB) and tuberculous meningitis (TBM); and BV200, a novel anti-virulence candidate targeting Staphylococcus aureus. These programs span lead optimization through Phase 3 clinical development, often in partnership with other organizations. BioVersys was founded as a university spin-off by Dr. Marc Gitzinger, who serves as Chief Executive Officer. Under his leadership, the company has raised over $70 million in equity financing and secured more than $30 million in non-dilutive funding, and has established partnerships with Big Pharma and development organizations. Dr. Gitzinger is a multi-award-winning biotech CEO, having received the Swiss Technology Award 2011, Venture Kick 2009, and Venture Leaders 2008 and 2017 awards. He is also President of the Board of the BEAM Alliance and a Board member of the AMR Industry Alliance. BioVersys is listed on the SIX Swiss Exchange, as indicated by its Chairman Seng Chin Mah being described as Chairman of BioVersys AG (a SIX-listed company). The company is headquartered in Basel, Switzerland, and operates globally through clinical development partnerships. Its board of directors includes experienced pharmaceutical and biotech leaders, and its team is described as world-leading experts in antibiotics with extensive scientific and clinical experience.
History
BioVersys AG was founded as a university spin-off by Dr. Marc Gitzinger, who serves as Chief Executive Officer. The company was established to address the growing threat of antimicrobial resistance (AMR) through the development of novel antibacterial therapies. Dr. Gitzinger, a multi-award-winning biotech CEO, has led the company from its early days to become a multi-asset clinical-stage organization. Under his leadership, BioVersys has raised over $70 million in equity financing and secured over $30 million in non-dilutive funding, and has established several important partnerships with Big Pharma and other development organizations. The company's pipeline has advanced through various stages of clinical development. BV100, a novel mechanism-of-action drug candidate for serious hospital infections caused by Acinetobacter baumannii, has progressed into later-stage trials. Alpibectir, a novel potentiator with a new mechanism of action for multidrug-resistant tuberculosis (MDR-TB) and tuberculous meningitis (TBM), is also in clinical development. BV200, a novel anti-virulence candidate targeting Staphylococcus aureus, is in earlier stages. These programs reflect BioVersys' commitment to addressing unmet medical needs in infectious diseases. BioVersys is listed on the SIX Swiss Exchange, as indicated by its Chairman Seng Chin Mah being described as Chairman of BioVersys AG (a SIX-listed company). The company is headquartered in Basel, Switzerland, and operates globally through clinical development partnerships. Its board of directors includes experienced pharmaceutical and biotech leaders, such as Seng Chin Mah, an independent healthcare advisor with over 30 years of experience in the Pharma and Biotech industry. The company's team is described as world-leading experts in antibiotics with extensive scientific and clinical experience, mixed with entrepreneurial thinking and a strong business sense.
- 2011
Dr. Marc Gitzinger receives Swiss Technology Award.
- 2009
Dr. Marc Gitzinger receives Venture Kick award.
- 2008
Dr. Marc Gitzinger receives Venture Leaders award.
Products and positioning
Clinical-stage biopharmaceutical company fighting antimicrobial resistance through innovative antibacterial therapies.
BV100
Novel mechanism-of-action drug candidate for serious hospital infections caused by Acinetobacter baumannii.
Alpibectir
Novel potentiator with a new mechanism of action for multidrug-resistant tuberculosis (MDR-TB) and tuberculous meningitis (TBM).
BV200
Novel anti-virulence drug candidate targeting Staphylococcus aureus.
Recent events
BioVersys receives CARB-X development funding[5]
Reported:
BioVersys announced US$3.94 million in non-dilutive funding from CARB-X for development of its BV200 anti-virulence program, with the possibility of an additional US$4.98 million if certain project milestones are met.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/bioversys-ag · Editorial policy · How profiles are compiled